Trials / Unknown
UnknownNCT00180882
LMBA02 Protocol for Patients With a Burkitt Lymphoma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 260 (planned)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rituximab |
Timeline
- Start date
- 2004-10-01
- First posted
- 2005-09-16
- Last updated
- 2006-09-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00180882. Inclusion in this directory is not an endorsement.